Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the tr…
$10.83-1.46%
报价 2026-11-13
市值
$601.9M
EV
$453.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -1.6%
$3.45$11.01
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.2x | -0.52 → -0.47 | — |
| FY+32028-12 | 1.3x | -0.52 → -0.47 | — |
毛利率 88% · TTM 收入 $88M · 基数 EPS -0.52(调整后)
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SGHTSight Sciences, Inc. | $601.9M | -1.5% | +19.1% | 88% | – | – | – | |
| SENSSenseonics Holdings, Inc. | $579.6M | +5.4% | +92.0% | 58.7% | – | – | – | 高增长 |
| MASS908 Devices Inc. | $405M | -0.5% | +26.7% | 49.8% | – | – | 911.9x | |
| CERSCerus Corporation | $400.9M | +2.3% | +10.4% | 52.1% | – | 226.7x | – | GARP |
| VMDViemed Healthcare, Inc. | $347.5M | +0.7% | +16.8% | 57% | 23.4x | 6.9x | 16.3x | GARP |
| LFCRLifecore Biomedical, Inc. | $243.4M | +0.3% | +62.7% | 29.7% | – | – | – | |
| PRQRProQR Therapeutics N.V. | $199M | +3.7% | – | 92.3% | – | – | – | |
| QTRXQuanterix Corporation | $139.1M | +2.4% | +27.6% | 41.7% | – | – | – | |
| CVRXCVRx, Inc. | $17.3M | -3.6% | +15.8% | 86.6% | – | – | – | |
| 同行中位数 | – | – | +26.7% | 54.5% | 23.4x | 116.8x | 464.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。